In the work of Zhu et al., the combination of Peg-IFNα with PD-1 blockade significantly enhanced tumor T-cell infiltration, increased the efficacy of anti-PD-1 antibodies, and improved mouse survival in a hepatocellular carcinoma model compared to anti-PD-1 antibody monotherapy [207]. This evidence concerns the gene IFNA2 and hepatocellular carcinoma.